Search Results
Results found for "Glaxo Inc"
- Dr. Terry Kenakin | Dr. GPCR Ecosystem
Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome
- Dr. Foord: Serendipity, RAMPs, And Industrial GPCR Pharmacology | Dr. GPCR Ecosystem
path from academic neuroendocrinology to introducing molecular biology and molecular pharmacology into Glaxo Foord is a physiologist and pharmacologist who spent more than two decades at Glaxo, Glaxo Wellcome, contributed to the identification of RAMPs in the CGRP receptor system, deorphanization of several GPCRs including and practical considerations in choosing receptor-rich tissues. 05:00 — Transition from academia to Glaxo
- Scott Struthers | Dr. GPCR Ecosystem
Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions
- Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem
Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. Prior to this, she held the position of Vice President, at Medarex, Inc . While at BMS and Medarex, she led programs from target ID to clinical development that included, CXCL10 She is an inventor on 39 issued U.S. patents including anti-PD-1 patents, 22 EP patents, and greater
- Steve McCloskey | Dr. GPCR Ecosystem
After graduating from UCSD he founded Nanome Inc to build Virtual Reality solutions for Scientists and
- Dr. Josh Pottel | Dr. GPCR Ecosystem
Josh Pottel "I lead Molecular Forecaster Inc.
- Dr. Juan José Fung | Dr. GPCR Ecosystem
Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused
- Dr. Patrick Sexton | Dr. GPCR Ecosystem
Sexton’s awards include the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists Sexton is also a co-founder of the San Francisco-based biotechnology company Septerna Inc . Dr.
- Dr. Bruno Giros | Dr. GPCR Ecosystem
doctoral training at the Pierre and Marie Curie University in Paris and a short internship at Genentech Inc with an H factor of 79 and 32,000 citations (Google Scholar) and has received several distinctions, including
- GPCR Masterclass Live Sessions | Dr. GPCR Ecosystem
Masterclass is included inDr. Masterclass is included in Dr.
- University | Dr. GPCR Ecosystem
Community forum & ecosystem access Intelligence Hub dashboard Grandfather guarantee — your rate never increases Grandfather guarantee: your rate never increases. No surprise charges.
- Dr. Tore Bengtsson: Rethinking β₂-Adrenergic Signaling in Metabolic Disease | Dr. GPCR Ecosystem
pharmacology of the β₂-adrenergic receptor , a GPCR traditionally associated with bronchodilation but increasingly opportunities to design drugs that promote beneficial metabolic responses such as muscle growth and increased Later I became increasingly interested in skeletal muscle metabolism and how β₂-adrenergic signaling
- Dr. Jennifer Pluznick: Olfactory Receptors in the Kidney and the Gut-Microbe Signal | Dr. GPCR Ecosystem
and therefore blood pressure; another regulates glucose handling through a transporter family that includes Pluznick's advice to early-career scientists is shaped by her own near-dismissal of an inconvenient microarray
- Dr. Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem
contributed to the identification of RAMP proteins, the GABA-B heterodimer, and ligands for orphan receptors including
- EARNEST Panel: Can AI Accelerate GPCR Drug Discovery? | Dr. GPCR Ecosystem
early cloning of GPCRs in the mid-1980s and has since pushed the boundaries of GPCR biochemistry — including Most pharmacology datasets aren't useless for ML; they're incomplete. Buffers, incubation temperatures, time points, co-expression conditions, the specific Emax reference
- Dr. Yamina Berchiche: Beyond the Lab — From Chemokine Receptors to the Dr. GPCR Ecosystem | Dr. GPCR Ecosystem
For the purposes of this presentation, I will walk you through my various career experiences and include
- Dr. Aaron Sato: Synthetic Antibody Libraries for the Hardest GPCR Targets | Dr. GPCR Ecosystem
already failed — not because the biology is easier, but because new technology is rewarded most where the incumbents an opportunity to tackle the challenge of identifying novel functional antibodies targeting GPCRs by incorporating
- Dr. J. Silvio Gutkind: When GPCRs Drive Cancer | Dr. GPCR Ecosystem
Current focuses include GαQ-driven uveal melanoma, GαS mutations across pancreatic, colon, and appendix Most large cancer sequencing panels now include these genes — though most oncologists are still unsure That insight is now powering focal adhesion kinase–directed clinical trials, including one Dr.
- Dr. Paul Insel: Rethinking COVID-19 Pathobiology Through GPCR Signaling | Dr. GPCR Ecosystem
training program at UCSD and has served as Editor or Senior Editor of numerous scientific journals, including
- Dr. Terry Hébert | Dr. GPCR Ecosystem
remotely; the continuity of receptor pharmacology work already in the pipeline before the shutdown, including
- Dr. Graciela Pineyro: Resilience, Lab Life, and the Zoom Effect | Dr. GPCR Ecosystem
GPCR Podcast; her earlier episode covers her scientific profile in depth, including her research trajectory whole conversation: the structural shifts forced by the shutdown — planned reflection, remote meeting inclusion
- Lauren Solano: Mapping Careers Beyond the Bench | Dr. GPCR Ecosystem
communicating across technical audiences — and introduces concrete tools for self-assessment and exploration, including Function over title Job titles in biotech are often creative and inconsistent — a medical science liaison
- Jacob Lee and Jin Cho: Rebuilding the Software Layer Under Modern Research | Dr. GPCR Ecosystem
One day as they were catching up, Jacob shared his struggles of managing samples and an incredible amount
- Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem
Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid The result: a six-hour feeding window for seven days increased morphine's antinociceptive efficacy in team focus on understanding how signal transduction cascades downstream of the opioid receptors work, including
- GPCR Masterclass: Advanced Pharmacology & Drug Discovery | Dr. GPCR
On-demand recordings are included inDr. Recipient of major honors including the ACS Smissman Award and the ASPET Goodman and Gilman Award for
- Dr. Maria Waldhoer: Pharmacological Fingerprints and the Limits of Bias | Dr. GPCR Ecosystem
academic group in Graz, she spent six and a half years at Novo Nordisk in early drug discovery, focused on incretin With comorbidities and aging populations driving drug discovery, the one-receptor-one-drug frame is increasingly eyeing industry or biotech 42:35 — On starting a GPCR company: why not too early 57:30 — Aha moments, including
- Dr. Anita Nivedha: Computational Dynamics of Ligand Bias in GPCR Signaling | Dr. GPCR Ecosystem
I also worked on collaborative projects involving peptide-binding receptors, including angiotensin receptors
- Dr. GPCR Board | Dr. GPCR Ecosystem
Discovering new aspects of PAR signaling is important for increasing the fundamental knowledge of GPCR
- Dr. Michael Feigin | Dr. GPCR Ecosystem
Scientific Journey and Drug Discovery Challenges Mike shared significant moments in his scientific journey, including
- Dr. Randy Hall | Dr. GPCR Ecosystem
Randy has received a number of research prizes, including the PhRMA New Investigator Award, the Distinguished




























